A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma

NCT06781112 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

TPF
Immunotherapy
Nasopharyngeal Carcinoma
Phase II Clinical Study

Interventions

DRUG: albumin paclitaxel (200mg/m2), cisplatin (60mg/m2, infused over 3 days), 5-fluorouracil (3000mg/m2, continuously intravenously pumped for 120 hours), and tislelizumab ( 200mg).

Sponsor

Weiwei Zhang